The direct effects of GLP-1 RAs on alcohol consumption, along with their favorable effects on obesity, T2DM, and MASLD, could lay the foundations to assess whether GLP-1 RAs could improve the long-term outcomes of patients whose liver disease has an alcohol or both an alcohol and a metabolic background (MetALD). Here, GCG is linked to obesity disorder.